Avalyn (AVLN) Stock Rated Buy Following Lung Disease Data

Jefferies has initiated coverage of Avalyn Pharma (AVLN) with a 'buy' recommendation. This decision comes on the heels of positive lung disease data from recent clinical trials, indicating potential growth opportunities for the company. The market could respond favorably as investors assess the implications of this data on Avalyn's long-term prospects. The initiation of coverage by a prominent firm like Jefferies suggests increased attention and potential investment interest in AVLN moving forward.